Vimentin Antibody (3CB2): sc-80975

Vimentin Antibody (3CB2) is a mouse monoclonal IgM antibody raised against vimentin extracted from chicken embryonic brain tissue, targeting vimentin, a 57 kDa intermediate filament protein crucial for cellular structure and function. Vimentin mouse monoclonal antibody (3CB2) recognizes an epitope within the vimentin immunogen sequence, providing researchers with a tool for studying cellular architecture and dynamics. The molecular structure of vimentin demonstrates remarkable organization: vimentin molecules form two-chain, α-helical, coiled-coil structures that assemble into extensive filamentous networks. These networks serve multiple functions beyond mere structural support - vimentin filaments create a dynamic scaffold that positions organelles, facilitates intracellular transport, and helps cells maintain their shape during mechanical stress. While vimentin predominantly localizes to the cytoplasm, vimentin′s distribution can shift during cell division or under specific stress conditions, reflecting vimentin′s role in cellular adaptation. Vimentin′s expression undergoes tight regulation, with vimentin participating in signaling cascades that influence cell motility, adhesion, and survival decisions. During epithelial-mesenchymal transition (EMT), vimentin expression increases significantly, marking this protein as a key player in processes ranging from cancer progression to wound healing and fibrosis. The frequent co-expression of vimentin with other intermediate filaments, particularly cytokeratins in various tumor types, makes vimentin an invaluable marker for tracking cancer metastasis and identifying tumor origins. Through these diverse functions in cellular architecture and signaling, vimentin serves as a central coordinator of cellular behavior. Vimentin (3CB2) antibody enables researchers to investigate both normal cellular processes and pathological conditions involving cytoskeletal dysfunction, providing insights into diseases characterized by altered cell structure and motility.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Vimentin Antibody (3CB2) References:

1. Vimentin contributes to changes in chondrocyte stiffness in osteoarthritis.  |  Haudenschild, DR., et al. 2011. J Orthop Res. 29: 20-5. PMID: 20602472
2. Aberrant vimentin methylation is characteristic of upper gastrointestinal pathologies.  |  Moinova, H., et al. 2012. Cancer Epidemiol Biomarkers Prev. 21: 594-600. PMID: 22315367
3. Vimentin disruption by lipoxidation and electrophiles: Role of the cysteine residue and filament dynamics.  |  Mónico, A., et al. 2019. Redox Biol. 23: 101098. PMID: 30658903
4. Oxidized LDL induces vimentin secretion by macrophages and contributes to atherosclerotic inflammation.  |  Kim, S., et al. 2020. J Mol Med (Berl). 98: 973-983. PMID: 32451671
5. Harmful vimentin manifests itself as multiorgan failure.  |  Eriksson, JE. 2020. Eur J Hum Genet. 28: 1139-1140. PMID: 32661328
6. Vimentin intermediate filaments stabilize dynamic microtubules by direct interactions.  |  Schaedel, L., et al. 2021. Nat Commun. 12: 3799. PMID: 34145230
7. Human Vimentin Layers on Solid Substrates: Adsorption Kinetics and Corona Formation Investigations.  |  Wasilewska, M., et al. 2022. Biomacromolecules. 23: 3308-3317. PMID: 35829774
8. Reconstitution of cytolinker-mediated crosstalk between actin and vimentin.  |  Petitjean, II., et al. 2024. Eur J Cell Biol. 103: 151403. PMID: 38503131
9. Interferon-induced MXB protein restricts vimentin-dependent viral infection.  |  Yi, D., et al. 2024. Acta Pharm Sin B. 14: 2520-2536. PMID: 38828143
10. Unique Role of Vimentin in the Intermediate Filament Proteins Family.  |  Alieva, IB., et al. 2024. Biochemistry (Mosc). 89: 726-736. PMID: 38831508

The preferred Vimentin antibody is Vimentin Antibody (V9): sc-6260.